ZYXI
Get informed when a big investor buys or sells
+ FollowUndervalued by 11524.9% based on the discounted cash flow analysis.
| Market cap | $3.80 Million |
|---|---|
| Enterprise Value | $62.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.09 |
| Beta | 1 |
| Outstanding Shares | 30,314,000 |
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.04 |
| Price to Book Ratio | -0.06 |
| Enterprise Value to Revenue | 0.57 |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.15 |
| Debt to Equity | -1.73 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.68%▼ 12.23% |
|---|---|
| Total Invested | $25,991▼ 99.54% |
| Investors Holding | 4▼ 51.00% |
No data
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord in...